Alzheimer’s disease (AD) is an irreversible, progressive neurological disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. AD affects people in all parts of the world, with age being the biggest risk factor. The incidence of AD is one in ten over the age of 65, one in two by age 90.
- Disease-modifying therapies for Alzheimer’s disease are urgently needed. There is a huge and growing market and patient population worldwide for Alzheimer’s disease and there is no disease-modifying drug No existing technologies under development have been shown to delay disease progression or provide significant patient benefit
- CENNA has a novel and different proprietary patented technology that arrests the underlying cause of the disease and that addresses previous failures by others
Cenna Biosciences is a biopharmaceutical company dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer’s disease. There is close to twenty years of academic research at the University of California at San Diego (UCSD) into this disease-modifying drug. Their target is A-Beta, which is the primary toxic insult in Alzheimer’s disease. It is now generally regarded as the first thing that goes wrong. Cenna is able to inhibit the production of A-Beta using a novel technology that addresses some of the problems encountered with previous attempts by others.J oin us as we explore the new discoveries on this important topic.
Featuring: Dr. Nazneen Dewji, President & Founder, Cenna Biosciences
Dr. Nazneen Dewji is the President and CEO of Cenna Biosciences Inc. and of Cura Therapeutics LLC, in La Jolla, CA and an Associate Adjunct Professor of Medicine at the University of California, San Diego. Nazneen was born in Tanzania and raised in England. She was educated at the University of London, where she earned her B.Sc. (Hons.) in Biochemistry and Ph.D. in Protein Chemistry and Enzymology. In 1986 she accepted a faculty position in the department of Medicine at UCSD. Since then she has worked on the molecular and cellular mechanisms in Alzheimer’s disease (AD). The discoveries made in her laboratory at UCSD support the development of new disease-modifying drug candidates for the treatment of AD. These are currently being developed at Cenna Biosciences Inc, a start-up company that she, along with her late colleague Dr. S. J. Singer, founded in 2006 and at Cura Therapeutics LLC that Nazneen founded in 2017. Cenna’s and Cura’s proprietary technologies address the underlying cause of the disease, the inappropriate deposition of the toxic species, ß-amyloid (Aß), in the brains of patients with AD. The Companies have developed novel targets and are developing several lead peptide and small molecule compounds as disease-modifying drug candidates for the treatment of AD. The work so far has been funded by non-diluting NIH and other grants. The Intellectual Property that forms the basis of Cenna’s and Cura’s approaches is covered by U.S. and foreign Patents.
5:30: Registration, Appetizers and Networking
7:45: Audience Q & A
8:00: Program Concludes, Networking, Coffee & Dessert until 8:30
REGISTRATION & COST
MITEF Members and MITEF Sponsors: Free
MIT Alums: $50
NOTE: Online Registration ends at midnight, the day prior to the event. If you register online the day of the event, you will be charged $75, the on-site price.
PAYPAL is our payment processor and accepts ALL MAJOR Credit Cards.